Approved: 19.01.2021
Revised: <date>

Statens legemiddelverk

OTC use in Norway for acetylsalicylic acid, ATC-code: B01AC06

- This OTC substance report is based on the assessment of the OTC indication and posology for products containing acetylsalicylic acid. It defines the preferred Norwegian wording for the package leaflet and labelling for OTC products containing acetylsalicylic acid. In addition, an overview of the approvable strength(s), pharmaceutical form(s) and pack size(s) exempt from medical prescription in Norway is included.

- The proposed OTC indication and posology in the OTC package leaflet and labelling must be covered by the information approved in the corresponding SmPC.

Preparations for oral use, up to 300 mg/unit

1. Package leaflet

1.1 Indication

Voksne over 18 år: ved mistanke om akutt hjerteinfarkt etter kontakt med 113.

1.2 Posology

Change the quantity from the given strength to the number of entities to be taken (e.g. 1–2 tablets, 1 suppository, 20 ml…). The text below include the posology and the necessary information included for the most commonly used pharmaceutical dose forms.

Voksne over 18 år:
- Ring 113.
- Ta <produktnavn> dersom du får beskjed om det.

2. Labelling

2.1 Indication

Voksne over 18 år: ved mistanke om akutt hjerteinfarkt etter kontakt med 113.

If the full indication is stated on the back panel of the package, the following abbreviation can be used on the front panel:

Ved mistanke om akutt hjerteinfarkt etter kontakt med 113

2.2 Posology

State the dosage as in the PIL.

2.3 Other information

Not applicable

3. Content of the pack

The table below presents the highest level of the terms for approvable pharmaceutical forms, if possible. For example: the term "tablets" includes all types of tablet formulations as for example film coated tablets or chewable tablets. For active substances where some pharmaceutical forms are exempt from approval due to safety concern, this is stated explicitly below the table.

Pharmaceutical form*	**Maximum strength**	**Maximum pack size**
Fast dissolving/fast acting oral formulations (e.g. granules, dispersible tablets, solution)	300 mg	1

*****For acetylsalicylic acid modified release products (delayed, modified, prolonged) are not approvable as OTC.

4. Additional risk minimisation measures

None